SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-146624
Filing Date
2021-05-03
Accepted
2021-05-03 07:18:02
Documents
16
Period of Report
2021-04-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d172053d8k.htm   iXBRL 8-K 44810
2 EX-10.1 d172053dex101.htm EX-10.1 44491
3 EX-10.2 d172053dex102.htm EX-10.2 51374
4 EX-10.3 d172053dex103.htm EX-10.3 54083
8 GRAPHIC g172053karyopharm.jpg GRAPHIC 4560
  Complete submission text file 0001193125-21-146624.txt   372231

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA kpti-20210427.xsd EX-101.SCH 3074
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20210427_lab.xml EX-101.LAB 18137
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20210427_pre.xml EX-101.PRE 11410
9 EXTRACTED XBRL INSTANCE DOCUMENT d172053d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 21881305
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences